US OptionsDetailed Quotes
BCDA241115P2500
- 0.00
- 0.000.00%
15min DelayClose Oct 31 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-7.30%PremiumNov 15, 2024Expiry Date0.17Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BioCardia Stock Discussion
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia has completed its Phase III CardiAMP HF trial, a randomized, double-blind, placebo-controlled study evaluating the CardiAMP Cell Therapy System for heart failure treatment. The trial enrolled 125 patients across 18 US hospitals, with 115 patients randomized 3:2 between treatment and control groups. The therapy, which received FDA Breakth...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
BioCardia (Nasdaq: BCDA), a leader in cardiovascular and pulmonary disease therapeutics, has announced the pricing of an upsized $7.2 million public offering. The offering includes 2,400,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 2,400,000 shares at $3.00 per share and accompanying warrant. The warrants have a 5-year expirati...
No comment yet